Polaprezinc

Summary

Polaprezinc is an oral prescription drug consisting of a zinc‑carnosine chelate. It is approved primarily for the treatment of gastric ulcers and as a zinc‑replacement therapy. The compound combines zinc with the dipeptide carnosine, delivering zinc directly to injured gastrointestinal mucosa while providing antioxidant and cytoprotective effects. Clinical research has examined its role in correcting zinc deficiency, enhancing Helicobacter pylori eradication when added to standard triple therapy, and supporting mucosal healing in various gastrointestinal disorders.

Mechanism of Action

Polaprezinc exerts its action through several linked pathways. The zinc‑carnosine complex binds preferentially to damaged epithelial cells, where ligand exchange releases zinc ions locally. Released zinc acts as a cofactor for antioxidant enzymes and directly quenches reactive oxygen species, reducing oxidative stress. Carnosine contributes metal‑chelating, anti‑glycation and anti‑cross‑linking activities, and modulates cytokine production. Together these actions stabilize cell membranes, suppress inflammation, and promote epithelial restitution via pathways such as p38 MAPK inhibition and nitric‑oxide‑mediated signaling, supporting mucosal repair.

What the Research Shows

A 2011 review highlighted polaprezinc’s reactive‑oxygen‑species‑quenching activity as part of gastric mucosal defense. A 2020 individual‑patient‑data meta‑analysis of four randomized trials showed that polaprezinc (75‑300 mg) increased serum zinc by an average of 9 µg/dL with a clear dose‑response, though higher doses were linked to more gastrointestinal adverse events. A 2022 meta‑analysis of three RCTs (396 participants) found that adding polaprezinc to standard triple therapy roughly doubled Helicobacter pylori eradication odds without raising overall adverse events. A 2022 narrative review described its cytoprotective, anti‑inflammatory, and membrane‑stabilizing actions in ulcer, oral mucositis, esophagitis, ulcerative colitis, and permeability disorders, supported by in‑vitro and limited human data. A systematic review of taste disorders noted zinc, including polaprezinc, may prevent or alleviate radiotherapy‑related taste loss. A 2018 review linked zinc‑carnosine to neuroprotective mechanisms, but clinical evidence for neurodegeneration remains absent.

Reported Benefits

Clinical trials demonstrate that polaprezinc reliably raises serum zinc levels, correcting mild deficiency. Its antioxidant and mucosal‑protective properties translate into faster ulcer healing and enhanced epithelial recovery. When combined with standard triple therapy, it significantly improves Helicobacter pylori eradication rates without adding safety concerns. Preliminary evidence suggests it may lessen taste disturbances in patients receiving head‑and‑neck radiotherapy. The compound’s dual zinc and carnosine actions also underpin broader gastrointestinal protective effects reported in small human studies.

Limitations of the Evidence

Evidence for many indications rests on a limited number of small randomized trials, especially for ulcer healing and taste‑disorder prevention, making effect estimates imprecise. The dose‑response benefit in zinc repletion is offset by a higher incidence of gastrointestinal complaints at larger doses. Neuroprotective claims are based on mechanistic reviews and animal data, with no clinical trials cited. Larger, well‑designed studies are needed to confirm long‑term efficacy and safety across diverse populations.

Safety Considerations

Polaprezinc is generally well tolerated. The 2020 meta‑analysis reported that all investigated doses were tolerable, but gastrointestinal adverse events (e.g., nausea, abdominal discomfort) increased with higher doses, particularly 300 mg. In the Helicobacter pylori adjunct trials, overall adverse event rates were comparable to standard therapy alone. No serious safety signals or organ toxicity were identified in the cited literature. Caution may be warranted in patients with severe gastrointestinal disorders or known zinc hypersensitivity.

How It Is Administered

Polaprezinc is administered orally, typically as tablets. Clinical studies have evaluated daily doses of 75 mg, 150 mg, and 300 mg, often divided into two doses. It is used as a prescription medication for ulcer treatment and as a zinc‑replacement supplement. No specific formulation details beyond oral tablets are provided in the abstracts.

Routes of Administration

Goals & Uses

• Taste disorder (dysgeusia) treatmentSensory/NeurologicalModerate
• H. pylori eradication (adjunct)Antimicrobial / GastrointestinalModerate
• Mucosal protectionProtective BarrierHigh
• Gastric ulcer healingGastrointestinalHigh
• Chemotherapy-induced oral mucositis preventionOncology Supportive CareModerate
• Inflammatory bowel diseaseGastroenterologyLow
• Gastroesophageal reflux disease (GERD) symptom reliefGastrointestinalLow
• Gastritis symptom reliefInflammation ControlModerate

Contraindications

• Hypersensitivity to polaprezinc or its componentsAllergyHigh
• Copper deficiencyMetabolicModerate
• Severe renal impairmentOrganModerateKidney function concerns
• Renal impairment (severe)RenalModerate
• Hypersensitivity to zinc or L‑carnosineAllergyHigh
• Use in children <12 yPediatricModerate

Adverse Effects

• Hepatic dysfunctionHepaticRare
• HeadacheNeurologicUncommonPain in the head or upper neck
• Metallic tasteSensoryCommon
• ConstipationGastrointestinalUncommonReduced bowel frequency or difficulty passing stool
• Copper deficiency (with long-term use)MetabolicRare
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Elevated serum zinc levelsMetabolicUncommon
• Transient liver enzyme elevationHepaticRare
• DiarrheaGastrointestinalCommonLoose or frequent stools

Drug Interactions

• Tetracycline antibioticsHigh
• Copper supplementsModerate
• Antacids (aluminum/magnesium)Moderate
• Iron supplementsModerate
• PenicillamineModerate
• Fluoroquinolone antibioticsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Severe renal impairmentOrgan ImpairmentRelative
• ElderlyAgeRelative
• LactationReproductiveRelative
• Pediatric populationAgeRelative

Regulatory Status

• European UnionUnapprovedNo EMA marketing authorization.
• JPApprovedApproved: gastric ulcerApproved since 2004.
• United StatesUnapprovedNot FDA‑approved; available as dietary supplement in limited forms.
• United KingdomUnapprovedNot approved by MHRA as a medicine. Available as a food supplement.

Approved in Japan (2004) for gastric ulcer; not approved by FDA or EMA.

Evidence & Sources

• Gastrointestinal defense mechanisms
  Journal ArticleModeratePalileo C, Kaunitz JD2011-01-01T00:00:00.000000Z
• Zinc, Carnosine, and Neurodegenerative Diseases
  Journal ArticleModerateKawahara M, Tanaka KI, Kato-Negishi M2018-01-01T00:00:00.000000Z
• Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data
  Journal ArticleHighFurihata K, et al.2020-01-01T00:00:00.000000Z
• Efficacy and Safety of Polaprezinc-Based Therapy versus the Standard Triple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  Journal ArticleHighMahmoud A, et al.2022-01-01T00:00:00.000000Z
• Taste disorder's management: a systematic review
  Journal ArticleHighBraud A, Boucher Y2020-01-01T00:00:00.000000Z
• The role of Zinc L-Carnosine in the prevention and treatment of gastrointestinal mucosal disease in humans: a review
  Journal ArticleModerateEfthymakis K, Neri M2022-01-01T00:00:00.000000Z

Frequently Asked Questions